Guggenheim Maintains Buy on Celldex Therapeutics, Raises Price Target to $100
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Yatin Suneja maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $90 to $100.
Guggenheim analyst Yatin Suneja maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $90 to $100.